Endocrine Abstracts

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing cause of hepatocellular carcinoma (HCCs); however, the molecular characteristics of MAFLD-derived HCCs are still to be elucidated. To provide novel insights in this field, we performed the first quantitative proteomic analysis of HCC samples from different aetiologies. Particularly, cytosolic and nuclear proteome of liver tissues from HCC patients (n=42; HCC vs adjacent tissue) and healthy contr...

Obesity (OB) is caused by an energy imbalance that finally leads to adipose tissue dysfunction, and the appearance of multiple comorbidities, such as certain cancer types, including prostate cancer (PCa), which is one of the leading causes of cancer-related death in men population worldwide. In this context, periprostatic adipose tissue (PPAT) has recently gained increased attention as a key regulator of the pathophysiological relationship between OB and PCa. However, it has b...

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETs can be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resection is the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are p...

A growing number of studies suggest that extracellular fragments derived from plasma membrane receptors can play relevant functional roles in the development and progression of certain tumoral pathologies which might, therefore, serve as novel tools in the diagnostic and prognostic of such pathologies. In this scenario, the truncated somatostatin receptor sst5TMD4, which is overexpressed in various endocrine-related cancers (i.e. breast, prostate, neuroendocrine, liver and pit...

Metabolic syndrome (MetS) and type-2 diabetes (T2D) development is critically affected by the loss of phenotypic flexibility (i.e. the difficulty to cope with stressors to maintain metabolic homeostasis). Thus, it is essential to identify key modifiers of phenotypic plasticity that define individual susceptibility to develop T2D. Particularly, there is emerging evidence that alternative mRNA splicing is dysregulated under adverse metabolic-conditions, such as T2D, in several t...

Pituitary adenomas (PA) comprise a commonly underestimated pathology in terms of incidence and associated morbimortality. Somatostatin and dopamine analogs constitute the main medical treatment for PA. However, an appreciable subset of patients are resistant or poorly responsive to these drugs, and hence, the search for new therapies to control tumor growth and/or hormone secretion is crucial. Biguanides such as metformin (MF; commonly used to treat type-2 diabetes), phenformi...

Somatostatin (SST) and cortistatin (CORT) are two highly related neuropeptides involved in the regulation of several endocrine secretions. In particular, SST and CORT are two primary negative regulators of GH secretion. Consequently, SST or CORT knockout (KO) mice exhibit elevated GH levels; however, this does not lead to increased IGF-I levels or somatic growth, which has been suggested that could be due to a compensatory mechanism between both peptides. In order to test this...

The presence of the truncated somatostatin receptor sst5TMD4 has been correlated with poor prognosis in breast cancer tumorsand its overexpression in breast cancer derived cell lines is associated with increased cell malignancy. The objective of this study was to examine the cellular and molecular mechanisms underlying this association in order to identify new molecular targets for diagnosis, prognosis or therapy of these tumors. Accordingly, in this study, a breast cancer der...

Objective: Cushing’s disease (CD) is difficult to diagnose because of its rarity and because its most common symptoms can overlap with those of other more common conditions. Remission rates in the postoperative vary between 55–85%. Overall, the mean time to diagnosis was 38 months. The objective of this study was to describe whether there is any pre-surgical clinical data that predicts CD remission after TSS.Patients and Methods: Retrospectiv...

Objective: Remission of Cushing’s disease (CD) in the postoperative vary between 55–85%, recurrence of up to 25%. Remission and recurrence rates vary dependent on tumor size and neurosurgical expertise. The objective of this study is to describe whether there are clinical data that help us to predece recurrence of CD after transsphenoidal surgery (TSS).Patients and Methods: Retrospective analysis of patients who underwent as TSS for CD. Varia...